Introduction: Diabetes mellitus (DM) is a significant comorbidity associated with adverse tuberculosis (TB) treatment outcomes and remains an ongoing clinical challenge. Chronic hyperglycemia impairs host immune responses, particularly macrophage function, leading to delayed bacillary clearance. This contributes to poorer outcomes, including delayed sputum conversion, prolonged treatment duration, relapse, and increased mortality. Poor glycemic control is a key modifiable factor influencing these outcomes. This study aimed to evaluate the impact of glycemic control at diagnosis on TB treatment outcomes in a Malaysian cohort. Methodology: A retrospective cross-sectional audit was conducted using the TB clinic registry at Hospital Sungai Buloh from 2022 to 2025. Adult patients (≥18 years) with confirmed TB (any form) and DM (Type 1 or Type 2) with complete records were included. Of 241 patients screened, 131 were included after exclusions due to incomplete records (29.9%), transfer (29.9%), loss to follow-up (19.9%), and drug-resistant TB (2.9%). Data collected included demographics, hemoglobin A1c (HbA1c) at diagnosis, sputum conversion duration, treatment duration, type of DM therapy, and clinical outcomes. Results: The cohort had a mean age of 53 years, with 97% having Type 2 DM. Mean HbA1c at diagnosis was 10.5%. Poorer glycemic control was associated with delayed sputum conversion. Patients who achieved sputum conversion by 8 weeks had an average HbA1c of 9.6%, compared to 11.8% in those with delayed conversion. Longer treatment duration was associated with higher HbA1c (mean 10.5, 8.6, and 11.8% for 6-, 12-, and 18-month regimens, respectively). Relapse analysis demonstrated a trend towards higher HbA1c with increasing relapse episodes (11.2, 13.75, and 14.5% for one, two, and three relapses, respectively). Overall mortality was 17% (22/131), with markedly higher mean HbA1c in deceased patients compared to survivors (16.0% vs 10.5%). Conclusion Poor glycemic control at TB diagnosis is associated with delayed sputum conversion, prolonged treatment duration, and increased mortality. These findings are consistent with regional evidence, including a South Asian systematic review (Gautam et al., 2021), demonstrating higher mortality and treatment failure in patients with TB and DM. Early and aggressive optimization of glycemic control, alongside standard anti-TB therapy, is essential to improve outcomes.
Humans ; Glycemic Control ; Retrospective Studies ; Diabetes Mellitus ; Treatment Outcome ; Tuberculosis

Introduction: Severe thyrotoxicosis is an endocrine emergency that may present with multiorgan dysfunction, particularly when precipitated by systemic infection. Management becomes challenging when hepatic injury limits the use of standard antithyroid therapy. We report a case of severe thyrotoxicosis with acute hepatitis in the setting of dengue IgM positivity. Case: A 44-year-old male with chronic alcohol use presented with epistaxis. On examination, he was deeply jaundiced and had tremors on outstretched hands. Initial investigations showed severe hepatitis with AST 2029 U/L, ALT 698 U/L, total bilirubin 236 µmol/L, alkaline phosphatase 138 U/L, and thrombocytopenia (34 ×10⁹/L). Viral hepatitis HBV, HCV, HIV, and autoimmune hepatitis screen were negative. Dengue IgM was positive. Thyroid function tests demonstrated overt thyrotoxicosis with free thyroxine 4 (FT4) 58.6 pmol/L and suppressed thyroid-stimulating hormone. He was managed as severe thyrotoxicosis with impending thyroid crisis in view of systemic illness and multiorgan involvement. Due to significant hepatic dysfunction, he was treated with propranolol, dexamethasone, and lithium carbonate 300 mg BD. Over 5 days, there was marked clinical improvement with resolution of tachycardia and tremors. FT4 decreased to 44.8 pmol/L. Liver function tests improved significantly (AST 157 U/L, ALT 195 U/L, bilirubin 163 µmol/L), and thrombocytopenia resolved (platelets 323 ×10⁹/L). He remained hemodynamically stable with normal Glasgow Coma Scale throughout admission. Conclusion This case highlights severe thyrotoxicosis with acute hepatitis and dengue infection, where management was complicated by contraindication to conventional antithyroid therapy. Lithium and corticosteroids provided effective biochemical and clinical improvement. Early recognition and individualized therapy are crucial in complex multisystem thyrotoxic presentations.
Hepatitis A ; Thyrotoxicosis ; Dengue